Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3NET 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 3Head and Neck Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Neuroendocrine Tumors 1Laryngeal Diseases 1Hypoxia 1HCC 1Carcinoma, Squamous Cell 1

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × Tirapazamine × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

NCT06848556 2025-02-27

Evaluate the Effect of Tirazamine on Primary Liver Cancer.

Zhejiang Raygene Pharmaceuticals Co., Ltd

Phase 1/2 Terminated
16 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03145558 2024-11-22

TATE

Teclison Ltd.

Phase 2 Terminated
6 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡